Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 1:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 206 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: NET Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Prospective Evaluation of Self-Testing to Increase Screening

NCT03898167
View directory record Official record
Conditions
Cervical Cancer, Human Papillomavirus Infection
Interventions
Telephone Recall, Mailed HPV Self-Sampling Kit, Patient Navigation
Behavioral
Lead sponsor
Baylor College of Medicine
Other
Eligibility
30 Years to 65 Years · Female only
Enrollment
2,474 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Jul 22, 2026, 1:56 AM EDT
Active, not recruiting Phase 3 Interventional

Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE

NCT04919226
View directory record Official record
Conditions
Neuroendocrine Tumors
Interventions
177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT, CAPTEM (Capecitabine and Temozolomide), Amino-Acid Solution, Everolimus, FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin)
Drug · Other
Lead sponsor
ITM Solucin GmbH
Industry
Eligibility
18 Years and older
Enrollment
259 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
14
States / cities
Palo Alto, California • Aurora, Colorado • Tampa, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Jul 22, 2026, 1:56 AM EDT
Completed Phase 1Phase 2 Interventional

A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients

NCT01262235
View directory record Official record
Conditions
Cancer, Neuroendocrine Tumors, NET, Adrenocortical Carcinoma, ACC
Interventions
TKM-080301
Drug
Lead sponsor
Arbutus Biopharma Corporation
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
8
States / cities
Scottsdale, Arizona • Tampa, Florida • Iowa City, Iowa + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2019 · Synced Jul 22, 2026, 1:56 AM EDT
Completed Phase 2 Interventional Results available

A Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated Biomarkers

NCT02132468
View directory record Official record
Conditions
Neuroendocrine Tumors
Interventions
fosbretabulin tromethamine
Drug
Lead sponsor
Mateon Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
5
States / cities
Stanford, California • Lexington, Kentucky • The Bronx, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2017 · Synced Jul 22, 2026, 1:56 AM EDT
Enrolling by invitation Not applicable Interventional

The Social Determinants of Health Screening and Referral Project

NCT06582147
View directory record Official record
Conditions
Preterm Birth
Interventions
Implementation of social determinants of health screening and referral
Other
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older · Female only
Enrollment
882 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
7
States / cities
Denver, Colorado • Jacksonville, Florida • Detroit, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Jul 22, 2026, 1:56 AM EDT
Recruiting Not applicable Interventional

Nutrition Intervention for Pancreatic Cancer

NCT07554560
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Neuroendocrine Tumor (NET)
Interventions
Structured Lipid Medical Food
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Jul 22, 2026, 1:56 AM EDT
Active, not recruiting No phase listed Observational

PET Imaging of Chronic Pain Syndromes

NCT03233594
View directory record Official record
Conditions
Chronic Pain Syndrome
Interventions
Chiropractic Group, Healthy Control Group
Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Villanova, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 24, 2025 · Synced Jul 22, 2026, 1:56 AM EDT
Recruiting Phase 3 Interventional

Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research Design

NCT07398417
View directory record Official record
Conditions
Fibromyalgia
Interventions
AXS-14 (Esreboxetine), Placebo
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
620 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
16
States / cities
Little Rock, Arkansas • Santa Ana, California • Cromwell, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Jul 22, 2026, 1:56 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors

NCT03043664
View directory record Official record
Conditions
Gastroenteropancreatic Neuroendocrine Tumors
Interventions
Lanreotide, Pembrolizumab
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
2
States / cities
Durham, North Carolina • Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Jul 22, 2026, 1:56 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

IText For ICOUGH: Improving Ambulation of Surgical Patients Through Text Messaging

NCT03834428
View directory record Official record
Conditions
Ambulation Difficulty
Interventions
Text Message Intervention, ICOUGH protocol
Behavioral
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 15, 2019 · Synced Jul 22, 2026, 1:56 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Family Safety Net - Aim 3: Randomized Control Trial

NCT05657119
View directory record Official record
Conditions
Suicide, Accidental Injuries, Firearm Injury
Interventions
MI FSN - Lethal Means Reduction, Scripted FSN - Lethal Means Reduction, General Firearm Safety Intervention - General Firearm Safety, General Firearm Comparison - General Firearm Safety
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Kotzebue, Alaska
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Jul 22, 2026, 1:56 AM EDT
Recruiting Phase 1 Interventional

A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit

NCT06805825
View directory record Official record
Conditions
Gastrointestinal Stromal Tumors, Small-cell Lung Cancer, Adenoid Cystic Carcinoma, Uveal Melanoma, Neuroendocrine Tumors, Chromophobe Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma
Interventions
NN3201
Drug
Lead sponsor
Novelty Nobility, Inc.
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
5
States / cities
Ann Arbor, Michigan • Cleveland, Ohio • Portland, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Jul 22, 2026, 1:56 AM EDT
Completed Phase 2 Interventional Results available

Heart Failure Polypill at a Safety Net Hospital

NCT06029712
View directory record Official record
Conditions
Heart Failure With Reduced Ejection Fraction, HIV Infections
Interventions
Heart failure polypill, Control Rx
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Jul 22, 2026, 1:56 AM EDT
Completed No phase listed Observational

Community-based Neuroendocrine Tumor (NET) Research Study

NCT02730104
View directory record Official record
Conditions
Gastroenteropancreatic Neuroendocrine Tumors
Interventions
Not listed
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
12
States / cities
Sedona, Arizona • Denver, Colorado • Arlington Heights, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2020 · Synced Jul 22, 2026, 1:56 AM EDT
Completed Not applicable Interventional Results available

Smoking Cessation for Cervical Cancer Survivors

NCT02157610
View directory record Official record
Conditions
Cervical Cancer, Tobacco Use, Smoking Cessation
Interventions
Self-Help Materials, Nicotine Patch, REDCap, Saliva Test, Telephone Counseling Sessions, Nicotine lozenge
Behavioral · Drug · Procedure
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
3
States / cities
Tampa, Florida • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jul 19, 2023 · Synced Jul 22, 2026, 1:56 AM EDT
Recruiting Phase 1 Interventional

[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers

NCT06479811
View directory record Official record
Conditions
Sinonasal Neuroendocrine Carcinoma, Nasopharyngeal Carcinoma, Esthesioneuroblastoma, Olfactory Neuroblastoma, Somatostatin Receptor Positive, Small Cell Lung Cancers, Pheochromocytoma/Paragangliomas, Kidney Cancers, Head and Neck Tumors, Gastrointestinal Neuroendocrine Tumors
Interventions
68Ga-DOTATATE, [203Pb]VMT-alpha-NET, [212Pb]VMT-alpha-NET
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Jul 22, 2026, 1:56 AM EDT
Completed Not applicable Interventional

The Effectiveness of Aromatherapy in an Urban, Safety-Net Hospital on Pain

NCT04840212
View directory record Official record
Conditions
Pain Management
Interventions
Lavender-Sandalwood scented aromatherapy sticker
Other
Lead sponsor
Parkland Health and Hospital System
Other
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 28, 2023 · Synced Jul 22, 2026, 1:56 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors

NCT07129252
View directory record Official record
Conditions
SST2-positive Neuroendocrine Neoplasms, Neuroendocrine Tumors, Neuroendocrine Neoplasm
Interventions
CRN09682
Drug
Lead sponsor
Crinetics Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
22
States / cities
Phoenix, Arizona • Duarte, California • Newport Beach, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Jul 22, 2026, 1:56 AM EDT
Recruiting No phase listed Observational

A Study of Treatment Patterns and Outcomes in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients

NCT07635316
View directory record Official record
Conditions
Gastroenteropancreatic Neuroendocrine Tumor
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 110 Years
Enrollment
4,023 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Jul 22, 2026, 1:56 AM EDT
Active, not recruiting Not applicable Interventional Results available

Testing a Novel Data-to-Suppression (D2S) Intervention Strategy in the Ryan White HIV/AIDS Program

NCT05140421
View directory record Official record
Conditions
Hiv
Interventions
Data to Suppression (D2S), Usual practice
Other
Lead sponsor
City University of New York
Other
Eligibility
Not listed
Enrollment
1,494 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
27
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Jul 22, 2026, 1:56 AM EDT
Not listed No phase listed Observational

"Assessment of Risk Factors for Depression Treatment at a Safety Net Clinic"

NCT00984685
View directory record Official record
Conditions
Depression
Interventions
Not listed
Lead sponsor
Scranton-Temple Residency Program
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Scranton, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 24, 2009 · Synced Jul 22, 2026, 1:56 AM EDT
Completed No phase listed Observational

A Study to Learn About the Dangers Linked to Myelosuppression (Decreased Bone Marrow Function) in Breast Cancer Patients Treated With the Study Medicine Palbociclib (Pal Bow Sai Klib)

NCT05709158
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
4,184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Jul 22, 2026, 1:56 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Safety Net Support Use in California

NCT04485377
View directory record Official record
Conditions
Households
Interventions
Not listed
Lead sponsor
University of California, Berkeley
Other
Eligibility
18 Years and older
Enrollment
501 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Aug 23, 2022 · Synced Jul 22, 2026, 1:56 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of MT-4561 in Patients With Various Advanced Solid Tumors

NCT06943521
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC), Esophageal Cancer, Gastric Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma (PDAC), Breast Cancer, Ovarian Cancer, Cervical Cancer, Endometrial Cancer, Prostate Cancer, Urothelial Carcinoma, Neuroendocrine Tumor (NET), Neuroendocrine Carcinoma (NEC), Soft Tissue Sarcoma, Nuclear Protein in Testis (NUT) Carcinoma
Interventions
MT-4561
Drug
Lead sponsor
Tanabe Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
4
States / cities
Los Angeles, California • Grand Rapids, Michigan • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Jul 22, 2026, 1:56 AM EDT